LeafNLP Demos
Back to explore

Report #2877640

Received Dec 12, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
FL
Recovered
Unknown
Vaccinated
Dec 8, 2025
Onset
Dec 8, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (ENGERIX-B)GLAXOSMITHKLINE BIOLOGICALS2N733B—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

second dose was administered three weeks apart from the first dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 38-year-old male patient who received HBV (Engerix B) (batch number N733B, expiry date 27-AUG-2027) for prophylaxis. Concomitant products included Hepatitis b vaccine rHBsAg (yeast) (Engerix b). On 08-DEC-2025, the patient received the 2nd dose of Engerix B. On 08-DEC-2025, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too short (Verbatim: second dose was administered three weeks apart from the first dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date:8-DEC-2025 The Vaccine Administration Facility was the same as primary reporter The reporter stated that, the second dose was administered three weeks apart from the first dose.